Literature DB >> 1734699

Vincristine-induced paralytic ileus: role of fiberoptic colonoscopy and prostaglandin F2 alpha.

O Ikehara1.   

Abstract

Two cases of vincristine-induced paralytic ileus are described, with therapeutic correlation. Both patients had a roentgenographic picture of paralytic ileus showing fecal mass in the ascending colon and dilated bowel loops. One patient was successfully treated with glycerin and saline enema through a fiberoptic colonoscope placed in the ascending colon. The second patient was successfully treated with intravenous prostaglandin F2 alpha (PGF2 alpha). Enema through a fiberoptic colonoscope or the intravenous administration of PGF2 alpha may, therefore, prove useful in the treatment of vincristine-induced gastrointestinal toxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1734699

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

1.  Prolonged gastrointestinal dysmotility in a patient with hemophagocytic lymphohistiocytosis treated with vincristine.

Authors:  T Tomomasa; R Miyazawa; M Kato; M Hoshino; M Tabata; H Kaneko; M Suzuki; T Kobayashi; A Morikawa
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

2.  Effect of vincristine on gastric motility in conscious rats.

Authors:  H Kaneko; T Tomomasa; T Watanabe; A Takahashi; M Tabata; S Hussein; A Morikawa
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

3.  Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.

Authors:  Kei Kawada; Tsuyoshi Ohta; Hitoshi Fukuda; Toshinobu Hayashi; Koudai Tanaka; Toshi Imai; Yasuyo Morita; Mitsuhiko Miyamura
Journal:  Ann Hematol       Date:  2020-08-24       Impact factor: 3.673

4.  Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat.

Authors:  Gema Vera; Ana E López-Pérez; José A Uranga; Rocío Girón; Ma Isabel Martín-Fontelles; Raquel Abalo
Journal:  Front Pharmacol       Date:  2017-02-06       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.